Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723656 · ClinicalTrials.gov registry record · NA
Proactive Care Coordination for Cancer Survivors Who Smoke
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 581
- Enrollment target
NCT02723656: Completed NA study, sponsored by NYU Langone Health.
NCT02723656 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 581 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02723656, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 581 participants
- Enrollment target
Study Summary
This is a population-based randomized controlled trial of 600 patients with a diagnosis of cancer in the past 2 years and registry indicating smoking at the time of diagnosis, that will inform critical questions regarding the relative efficacy of care coordination options, the reliability of Electronic Health Record (EHR) tobacco use data, and how patients will react to proactive tobacco related communications. Investigators will compare the reach and efficacy of two proactive approaches to enrolling cancer survivors in tobacco treatment (Arm 1: mailed care coordination vs. Arm 2: telephone care coordination) using a two-arm randomized design at two urban cancer centers, and will explore cancer survivor attitudes and preferences about proactive tobacco treatment.
Interventions
- BEHAVIORAL Online Referral NYS Quitline
- BEHAVIORAL Tobacco cessation counseling and coordination of cessation medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-09-29 |
| Phase | NA |
What the finished NCT02723656 record still lists
NCT02723656 is an interventional study that assigns participants to a tested intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Online Referral NYS Quitline is the first listed.
NCT02723656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02723656 about?
NCT02723656 is a clinical study titled "Proactive Care Coordination for Cancer Survivors Who Smoke". This is a population-based randomized controlled trial of 600 patients with a diagnosis of cancer in the past 2 years and registry indicating smoking at the time of diagnosis, that will inform critical questions regarding the relative efficacy of care coordination options, the reliability of Electro...
What is the current status of trial NCT02723656?
This trial is currently completed. It is a NA study. The enrollment target is 581 participants. The study started on 2016-03. Estimated completion is 2018-09-29.
What interventions are being tested in trial NCT02723656?
The interventions under investigation include: Online Referral NYS Quitline (BEHAVIORAL), Tobacco cessation counseling and coordination of cessation medications (BEHAVIORAL).
Who is sponsoring clinical trial NCT02723656?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02723656's enrollment target sits among peer trials
581 177th of 2000 higher than 1,824 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia